<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079194</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2014-01-161</org_study_id>
    <nct_id>NCT02079194</nct_id>
  </id_info>
  <brief_title>Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES</brief_title>
  <acronym>SMART-CHOICE</acronym>
  <official_title>Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12
      antagonist following 3-month of DAPT in patients undergoing PCI with DES.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, randomized, multi-center, open label, noninferiority trial.
      Patients undergoing PCI with DES will be eligible. After successful PCI with DES, all
      eligible patients will be randomized either to clopidogrel monotherapy or to aspirin plus
      P2Y12 antagonist following 3-month of DAPT.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of death, myocardial infarction, or cerebrovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>12 months after the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause Death</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident (CVA)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis: definite or probable stent thrombosis by ARC definition</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding ≥2</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding ≥3</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiocerebral event (MACCE): death, MI, CVA, or any revascularization</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>P2Y12 antagonist monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P2Y12 antagonist monotherapy after 3-month DAPT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin + P2Y12 antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin + P2Y12 antagonist after 3-month DAPT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2Y12 antagonist monotherapy</intervention_name>
    <arm_group_label>P2Y12 antagonist monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin plus P2Y12 antagonist</intervention_name>
    <arm_group_label>Aspirin + P2Y12 antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be at least 20 years of age.

          -  Subject is able to verbally confirm understandings of risks, benefits and treatment
             alternatives and he/she or his/her legally authorized representative provides written
             informed consent prior to any study related procedure.

          -  Patients undergoing successful PCI

        Exclusion Criteria:

          -  Hemodynamic instability or cardiogenic shock

          -  Active bleeding

          -  Known hypersensitivity or contraindication to study medications

          -  Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).

          -  DES implantation within 12 months before index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac and Vascular Center; Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeon-Cheol Gwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Drug-eluting stents</keyword>
  <keyword>aspirin</keyword>
  <keyword>P2Y12 antagonist monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

